Log in

OTCMKTS:CXRXFAdvanz Pharma Stock Price, Forecast & News

$3.45
-0.01 (-0.29 %)
(As of 06/1/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.18
Now: $3.45
$3.55
50-Day Range
$3.14
MA: $3.52
$4.55
52-Week Range
$2.50
Now: $3.45
$19.14
Volume23,821 shs
Average Volume27,032 shs
Market Capitalization$168.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia International Corp. and changed its name to ADVANZ PHARMA Corp. in November 2018. ADVANZ PHARMA Corp. is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.59 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CXRXF
CUSIPN/A
CIKN/A
Phone905-842-5150

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$508.32 million
Book Value$4.02 per share

Profitability

Net Income$-196,020,000.00

Miscellaneous

Employees435
Market Cap$168.75 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CXRXF News and Ratings via Email

Sign-up to receive the latest news and ratings for CXRXF and its competitors with MarketBeat's FREE daily newsletter.

Advanz Pharma (OTCMKTS:CXRXF) Frequently Asked Questions

How has Advanz Pharma's stock been impacted by COVID-19 (Coronavirus)?

Advanz Pharma's stock was trading at $3.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CXRXF stock has decreased by 3.9% and is now trading at $3.45. View which stocks have been most impacted by Coronavirus.

When is Advanz Pharma's next earnings date?

Advanz Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Advanz Pharma.

How were Advanz Pharma's earnings last quarter?

Advanz Pharma Corp (OTCMKTS:CXRXF) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.18) earnings per share for the quarter. The firm earned $129.99 million during the quarter. Advanz Pharma had a negative return on equity of 66.95% and a negative net margin of 39.13%. View Advanz Pharma's earnings history.

Has Advanz Pharma been receiving favorable news coverage?

Media stories about CXRXF stock have been trending very positive on Tuesday, according to InfoTrie. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Advanz Pharma earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAdvanz Pharma.

Who are some of Advanz Pharma's key competitors?

Who are Advanz Pharma's key executives?

Advanz Pharma's management team includes the following people:
  • Mr. Graeme Neville Duncan, CEO & Director (Age 45)
  • Mr. Karl Ian Belk, Chief Operations Officer (Age 51)
  • Mr. Adeel Ahmad, Chief Financial Officer (Age 45)
  • Mr. Robert Sully, Gen. Counsel (Age 46)
  • Mr. Paul Burden, Pres of U.K. & Ireland and Corp. Communications (Age 44)

What is Advanz Pharma's stock symbol?

Advanz Pharma trades on the OTCMKTS under the ticker symbol "CXRXF."

How do I buy shares of Advanz Pharma?

Shares of CXRXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Advanz Pharma's stock price today?

One share of CXRXF stock can currently be purchased for approximately $3.45.

How big of a company is Advanz Pharma?

Advanz Pharma has a market capitalization of $168.75 million and generates $508.32 million in revenue each year. Advanz Pharma employs 435 workers across the globe.

What is Advanz Pharma's official website?

The official website for Advanz Pharma is www.advanzpharma.com.

How can I contact Advanz Pharma?

Advanz Pharma's mailing address is 5770 HURONTARIO STREET SUITE 310, MISSISSAUGA A6, L5R 3GB. The company can be reached via phone at 905-842-5150 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.